Pfizer receives Breakthrough Therapy designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced its once-daily oral Janus kinase 1 (JAK1) inhibitor PF-04965842 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with moderate-to-severe atopic dermatitis (AD). The Phase 3 program for PF-04965842 initiated in December and is the first trial in the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program.
Merck is celebrating its anniversary by conducting 350 charitable activities in around 60 countries
- Details
- Category: Merck Group
Merck, a leading science and technology company, is celebrating its anniversary by conducting 350 charitable activities in around 60 countries. Taking responsibility has always been an integral part of the entrepreneurial approach of Merck and is one of its six values. On the occasion of its 350th anniversary, the company will further intensify its social engagement activities together with its employees.
Roche purchases shares in tender offer for Ignyta, Inc.
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Ignyta, Inc. (NASDAQ: RXDX) at a price of USD 27.00 per share in cash.
Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease
- Details
- Category: AstraZeneca
AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV death, myocardial infarction, or stroke) (HR 0.81; 95% CI, 0.7-0.95) and of 36% in coronary death (HR 0.64; 95% CI, 0.45-0.89) from treatment with Brilinta 60mg (ticagrelor), in combination with low dose aspirin, in people who had survived a heart attack and had stenosis (abnormal narrowing) in two or more coronary blood vessels, a condition known as multi-vessel disease (MVD).
Merck celebrates its 350th anniversary
- Details
- Category: Merck Group
Merck, a leading science and technology company, will celebrate its 350th anniversary this year with customers, partners and employees under the motto "Past. Present. Future." In 1668, the pharmacist Friedrich Jacob Merck laid the cornerstone for what Merck is today - a vibrant, global science and technology company.
Roche reports good results in 2017
- Details
- Category: Roche
In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS basis net income decreased 9% at CER. The IFRS result includes charges for the impairment of goodwill and intangible assets and the amortisation of intangible assets.
Advanced Accelerator Applications receives FDA approval for Lutathera® for treatment of gastroenteropancreatic neuroendocrine tumors
- Details
- Category: Novartis
Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new drug application (NDA) for Lutathera® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors, in adults.
More Pharma News ...
- Sanofi to acquire Ablynx for €3.9 Billion
- Pfizer announces positive top-line results for potential biosimilar to Rituxan® / MabThera®
- AstraZeneca listed as one of the world's top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage
- Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
- New research paper shows that AstraZeneca has achieved greater than four-fold improvement in R&D productivity
- Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
- FDA report reaffirms safety profile and effectiveness of Bayer's Xarelto® in routine clinical practice